<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table border="1" cellspacing="0" cellpadding="0" width="98%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th bgcolor="#cccccc" valign="top" align="left"&gt;&lt;p&gt;&lt;strong&gt;Center&lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;th bgcolor="#cccccc" valign="top" align="left"&gt;&lt;p&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;th bgcolor="#cccccc" valign="top" align="left"&gt;&lt;p&gt;&lt;strong&gt;Time&lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;th bgcolor="#cccccc" valign="top" align="left"&gt;&lt;p&gt;&lt;strong&gt;Location&lt;/strong&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;p&gt;CBER&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p&gt;November 18-19, 2009&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p&gt;November 18, 2009 from 8:00 a.m. to approximately 5:45 p.m.&lt;br /&gt;November 19, 2009 from 8:00 a.m. to approximately 3:15 p.m.&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p&gt;Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h3&gt;Agenda&lt;/h3&gt;&lt;p&gt;On November 18, 2009, the committee will discuss and make recommendations on the safety and effectiveness of a Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), BLA125324, and will hear an update on FDA&amp;rsquo;s Influenza A (H1N1) 2009 monovalent vaccine activities; Post-marketing surveillance. On November 19, 2009, the committee will discuss and make recommendations on the safety and effectiveness of an Influenza Vaccine, Purified Recombinant Influenza Hemagglutinin, BLA STN125285.&lt;/p&gt;&lt;h3&gt;&lt;a href="[!--$ssLink(&amp;quot;ucm129568.htm&amp;quot;)--]"&gt;Meeting Materials&lt;/a&gt;&lt;/h3&gt;&lt;p&gt;Public Participation Information&lt;/p&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul type="disc"&gt;&lt;li style="margin: 0pt"&gt;Written submissions may be made to the contact person on or before November 16, 2009&lt;/li&gt;&lt;li style="margin: 0pt"&gt;Oral presentations from the public will be scheduled between approximately 1:20 p.m. and 1:50 p.m. on November 18, 2009, and approximately 1:30 p.m. and 2 p.m. on November 19, 2009. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 9, 2009. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 10, 2009.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Closed Committee Deliberations&lt;/p&gt;&lt;p&gt;On November 19, 2009, from 8 a.m. to approximately 9 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential commercial information (5 U.S.C.552b(c)(4)).&lt;/p&gt;&lt;h3&gt;Contact Information&lt;/h3&gt;&lt;ul&gt;&lt;li&gt;Christine Walsh, R.N.&lt;br /&gt;1401 Rockville Pike, HFM-71, Rockville, MD 20852&lt;br /&gt;301-827-0314&lt;br /&gt;FAX: 301-827-0294&lt;br /&gt;e-mail: &lt;a href="mailto:Christine.Walsh@fda.hhs.gov"&gt;Christine.Walsh@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138 (301-443-0572 in the Washington, DC, area)&lt;br /&gt;code 3014512391. Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Christine Walsh or Denise Royster at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for &lt;a href="[!--$ssLink(&amp;quot;ucm111462.htm&amp;quot;)--]"&gt;procedures on public conduct during advisory committee meetings&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
